Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.

Einstein (Sao Paulo, Brazil) - 1 Jan 2026

Amarger Caroline Dotto, Rabello Maria Isabel de Sampaio, Skaf Sofia Chaves, Moura Fernando, Cassoli Janaína Pontes Batista, Taranto Patrícia, Serrano Usón Junior Pedro Luiz, Kaliks Rafael, Beal Juliana Rodrigues

Abstract excerpt

Breast cancer is one of the most prevalent and heterogeneous cancers worldwide; however, it remains a complex and enigmatic disease. Advances in targeted therapies combined with increasing knowledge about tumor subtypes and molecular profiling have placed precision medicine on the frontier of oncological treatments. The recent classification of certain HER2 tumors as HER2-low, along with emerging evidence from...

Topics

Join the communities discussing this publication.

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Camptothecin
Erb-b2 Receptor Tyrosine Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Immunoconjugates

Treatment Outcome

Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41538481
DOI: 10.31744/einstein_journal/2026RC1689
PMCID: PMC12714068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.PMID 41538481Read ↗

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read ↗

Low and Ultra-low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic SubtypesSemantic proximity Read ↗

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.Semantic proximity Read ↗

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read ↗

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugsSemantic proximity Read ↗

Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.Semantic proximity Read ↗

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.